2026 Payer IT Outsourcing Outlook: Outcome-Based Managed Services, Production-Grade GenAI Governance, and Vendor-Risk Enforcement 
Anaveon presents updated data from the Phase I/II study of ANV419 during the ESMO Congress 2022
- ANV419 is well-tolerated at high doses and demonstrates notable safety with strong pharmacodynamic effects and excellent IL-2Rbg selectivity –...
Novartis Cosentyx® shows clinically meaningful symptom improvements in patients with hidradenitis suppurativa in pivotal Phase III trials
Results from two parallel trials show Cosentyx® (secukinumab) demonstrated superior efficacy vs placebo with statistically significant improvement in hidradenitis suppurativa...
Ultragenyx and Mereo BioPharma to Present Setrusumab Data Update at ASBMR
NOVATO, Calif. and MOUNTAIN VIEW, Calif. and LONDON, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), (“Ultragenyx”),...
Chalice Brands Ltd. Announces Termination of Totem Farms & Miracle Greens Transactions
PORTLAND, Ore., Sept. 09, 2022 (GLOBE NEWSWIRE) -- Chalice Brands Ltd. (CSE: CHAL) (OTCQB: CHALF) (the “Company” or “Chalice Brands”),...
Jushi Holdings Inc. Files Restated First Quarter 2022 Financial Statements
BOCA RATON, Fla., Sept. 09, 2022 (GLOBE NEWSWIRE) -- Jushi Holdings Inc. (“Jushi” or the “Company”) (CSE: JUSH) (OTCQX: JUSHF),...
Prenetics Announces Second Quarter 2022 Financial Results and Raises Full Year Adjusted EBITDA Outlook
Revenue of US$51.7 million in the second quarter of 2022Loss from operations of US$(17.9) million and adjusted EBITDA1 of US$6.5...
Smart For Life to Present at the H.C. Wainwright 24th Annual Global Investment Conference
MIAMI, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Smart for Life, Inc. (Nasdaq: SMFL) (“Smart for Life” or the “Company”), a...
Erasca to Present at the Morgan Stanley Global Healthcare Conference
SAN DIEGO, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on...
ABVC BioPharma Selects Additional Vitargus® Phase II Study Site
New Australia Site Confirmed to Participate in the Study FREMONT, CA, Sept. 09, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire –...
SCYNEXIS to Participate in Upcoming September Investor Conferences
JERSEY CITY, N.J., Sept. 09, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to...
New Data from Arcutis’ STRATUM Pivotal Phase 3 Trial of Roflumilast Foam 0.3% in Seborrheic Dermatitis Presented at European Academy of Dermatology and Venereology (EADV) Congress
Study met its primary endpoint with 80% of individuals treated with roflumilast foam achieving Investigator Global Assessment (IGA) Success compared...
Catalyst Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
CORAL GABLES, Fla., Sept. 09, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused...
Immunovant to Present at the H.C. Wainwright 24th Annual Global Investment Conference on September 14th
NEW YORK, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company committed to enabling normal...
Sensus Healthcare to Present at the H.C. Wainwright 24th Annual Global Investment Conference
BOCA RATON, Fla., Sept. 09, 2022 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in...
Humacyte Announces Presentation on Investigational Human Acellular VesselTM for Treatment of Vascular Trauma at the International Committee of Military Medicine World Congress
Dr. Todd E. Rasmussen provides HAV™ clinical update and surgical skills workshop at ICMMDURHAM, N.C., Sept. 09, 2022 (GLOBE NEWSWIRE)...
Origin Therapeutics Announces New Director
Vancouver, B.C., Sept. 09, 2022 (GLOBE NEWSWIRE) -- Origin Therapeutics Holdings Inc. (CSE: ORIG) (the “Company” or “Origin Therapeutics”), an...
Compass Therapeutics to Present at the 24th Annual H.C. Wainwright Global Investment Conference
BOSTON, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics...
TG Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
Fireside chat available for on demand download beginning Monday, September 12 2022 at 7:00 AM ETNEW YORK, Sept. 09, 2022...
Excision BioTherapeutics to Present at Upcoming Conferences
SAN FRANCISCO, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Excision BioTherapeutics Inc., a clinical-stage biotechnology company developing CRISPR-based therapies intended to...
InflaRx to Present at Upcoming Scientific and Investor Conferences
JENA, Germany, Sept. 09, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by...